Estimation of Xanthine oxidase activity, related with Nitric oxide (NO) and lipid profile in serum of patients with atherosclerotic diseases | ||
| Journal of University of Anbar for Pure Science | ||
| Article 24, Volume 3, Issue 2, August 2009, Pages 88-94 PDF (322.61 K) | ||
| Document Type: Research Paper | ||
| DOI: 10.37652/juaps.2009.15394 | ||
| Author | ||
| Muthanna O. Hussein* | ||
| University of Anbar - College of Education for pure Education. | ||
| Abstract | ||
| This research outlines the study of xanthine oxidase activity (XO) , nitric oxide (NO) ) and lipid profile with an atherosclerotic disease(angina and cerebral thrombus) . The study covers 46 atherosclerotic disease patients (26 males , 20 females ) and 29 healthy subjects (control group) .The two groups contain males and females whose ages ranged between (38-65) years .The parameters ; Xanthine oxidase activity (XO) , Nitric oxide (NO) and lipid profile were investigated .The results of these subjects studied (patient and control group) have significant increase in the activity of Xantine oxidase and concentration of Nitric oxide, triglyceride, cholesterol, low density lipoprotein and very low density lipoprotein in the serum of atherosclerotic diseases (angina and cerebral thrombus) compared to control groups. The increase amounts are to 360%, 240%, 2.3%, 23.5%, 54.8% and 2.3% respectively as compared to control groups.The result indicates a significant decrease in the concentration of high density lipoprotein (HDL). The decrease amounts to 27% as compared to control groups. On the other hand, the results of these subjects studied show no significant different parameters in sex . | ||
| Keywords | ||
| Xanthine oxidase; Nitric oxide; Lipid profile; Serum; atherosclerotic diseases | ||
| References | ||
|
1-Ackermann E and Brill A .(1974). “Xanthin oxidase activity in method of enzymatic analysis” ed. Bergmeyer H.U., 2nd ed.,Academic press Inc. U.S.A, 521-522.
2-DavidE.metzler.(2004). “Biochemistry the chemical reaction of living cells” volums 1and 2 second edition , 16: 890-891 .
3- Wolthers K and Schimerlik M. (2001). “Biochemistry”, 40: 4722 – 4737.
4 – Robert K. Daryl K. Peter A. and Victor W.(2006). “ Harper’s Illustrated Biochemistry” , twenty-sixth edition ,49:571-572.
5- Chan N. Rogers P and Arnone A. (1998). “Biochemistry “, 37: 1459 – 1464
6-Schelvis, J. P. M., Zhao, Y, Marletta, M. A and Babcock, G. (1998) “Biochemistry”, 37:16289 – 16297.
7-Roberts S. Weichsel A. Qiu Y. Shelnutt J. Walker F. and Montfort, W. (2001).”Biochemistry” 40: 1327 – 1337.
8- Jeremy M.John L.Lubert Stryer. (2003). “Biochemistry fifth edition”, 49:686-687.
9- Ghosh, D. K., and Stuehr, D. J. (1995) “Biochemistry”, 34, 801 – 807
10-Ackermann E and Brill A.(1974). “Xanthin oxidase activity In method of enzymatic analysis” ed. Bergmeyer H.U.2nd ed., academic press inc., USA, 512-522.
11-Vanuffelen B.E., Van Derzec J. and DekosterB.M.(1998).Biochem.J., 330,719 ,cited by Al-Zamely et al (2001).
12-Friedewald W. Levy R and Fredrictson D.(1972). “Estimation of low density lipoprotein cholesterol in plasma without use of the preparative ultra centrifuge” .Clin.Chem, 18(6):499-502.
13. Shishehbor M .Aviles R and Brennan M.(2003). “Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy”. JAMA; 289:1675–1680.
14. Shishehbor M. Brennan M and Aviles RJ. (2003). “Statins promote potent systemic antioxidant effects through specific inflammatory pathways”. Circulation; 108:426–431.
15-katzung B.nitric oxide ,Donors and inhibitors . in :Basic and Clinical pharmacology. 8th ed., Lange medical books /Mc graw-Hill Medical publishing Division , New Yourk , PP. 326–332.
16-NCEP: The National Cholesterol Education program Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Third report ( adult treatment panel III). JAMA 2004; 585: 2486- 2497.
17-Keilani T. Schlueter W and Battle D. (1995). “Selected aspects of ACE inhibitor therapy for patients with renal disease impact on proteinuria, lipids and potassium”. J. Clin. Phramacol.; 35(1): 87- 97.
18-Krentz Z. (1996). “Insulin resistance”. B. M. J. 313 (30): 1385- 1389.
19-Stensvold I. tverdal A. Urdal P and Graff leversen S.(1993). “Non fasting serum triglycerides concentration and mortality from coronary heart disease and cuase in middle aged Norwegian women”. B. M. J. 307(20): 1318- 1322.
20-Grundy S . (1997). “Small LDL, atherogenic dyslipidemia and the metabolic syndrome (editorial; comment)”. Circulation; 95: 1-4.
21-Baghdad J . Albers J . (1977). “Plasma high- density lipoprotein concentrations in chronic hemodialysis and renal disease patients”. N. Eng. J. Med.; 296: 1436- 1439.
22-Deckelbaum R . Granot E and Oscry Y.(1994). “Plasma TG determines strudture- composition in low- and high density lipoproteins. Arteriosclerosis”. 4: 225- 231.
23-Karpati I. Paragh G and Kovacs E. (1999). “Disturbed LDL and scavenger receptor functions in monocytes from chronic hemodialysed patients”. Nephrol. Dial. Transplant.; 14: 2664- 2668.
24-Akira K. Yoshinori M. Isao O and Kazuki N. (2001).“relationship between triglycerides concentration and LDL size evaluated by malondialdehyde modified LDL”. Clinical chemistry, 479(5): 893- 900. | ||
|
Statistics Article View: 231 PDF Download: 68 |
||